Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sangbaipi decoction is a traditional Chinese medicine (TCM) herbal formula historically used to treat lung diseases characterized by phlegm-heat obstruction and respiratory symptoms such as cough, wheezing, and asthma. The formula is referenced in classical TCM texts like Jingyue Quanshu and is composed of multiple herbs with anti-pyretic (fever-reducing), antitussive (cough-suppressing), anti-inflammatory, antiviral, and diuretic properties. Key ingredients include Scutellaria baicalensis Georgi (Huang Qin), Coptis chinensis Franch. (Huang Lian), Cortex Mori (Sang Bai Pi/White Mulberry Root Bark), and Armeniacae Semen Amarum. Modern pharmacological studies have demonstrated that Sangbaipi decoction exhibits both in vitro and in vivo anti-influenza activity by inhibiting viral replication—potentially through effects on hemagglutinin and neuraminidase—and exerts significant anti-inflammatory effects[1][10]. It has also been widely applied for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in China[2][4]. The mechanism of action involves multi-target modulation including antiviral activity against influenza virus proteins as well as immunomodulatory actions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sangbaipi decoction.